Novo Nordisk Education Foundation launches Chatbot, Mishti for diabetes management in India

Published On 2021-07-20 05:45 GMT   |   Update On 2021-07-20 11:53 GMT

New Delhi: Novo Nordisk Education Foundation on Monday said it has launched Chatbot, Mishti aiming to provide access to important information to effectively manage diabetes in India.It is customised in seven different languages -- English, Hindi, Bengali, Gujarati, Marathi, Punjabi, and Tamil, so that a greater number of people can access the information in their preferred language, Novo...

Login or Register to read the full article

New Delhi: Novo Nordisk Education Foundation on Monday said it has launched Chatbot, Mishti aiming to provide access to important information to effectively manage diabetes in India.

It is customised in seven different languages -- English, Hindi, Bengali, Gujarati, Marathi, Punjabi, and Tamil, so that a greater number of people can access the information in their preferred language, Novo Nordisk Education Foundation (NNEF) said in a statement.

Some of the key information services offered by Mishti include insulin device demos, customised diet plans for each patient with exercise guidance based on publicly available information, and scientifically backed research papers, it added.

Read also: Unichem Labs diabetes drug Sitagliptin gets USFDA approval

"The pandemic has made us realise the importance of effectively managing diabetes to prevent various complications and co-morbidities. With digital transformation being the need of the hour, we must constantly innovate to provide digital solutions with a patient-centric approach," NNEF Managing Trustee Vikrant Shrotriya said.

Mishti delivers diabetes-centric information to people through Whatsapp, NNEF said.

Read also: Semaglutide to be sold only on prescription of Endocrinologist, PG Medicine in India: CDSCO Committee



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News